Annovis Bio (NYSE: ANVS), a Phase 3 clinical-stage biotechnology company developing treatments for neurodegenerative diseases, announced that President and CEO Maria Maccecchini, Ph.D., will present at Fierce Biotech Week 2026 in Boston on May 13. Her presentation will focus on the scientific basis for treating Alzheimer's disease as a multi-protein disorder, highlighting Annovis' approach of targeting multiple neurotoxic proteins simultaneously through its lead drug candidate, buntanetap.
Buntanetap, formerly known as posiphen, is an investigational once-daily oral therapy that inhibits the translation of multiple neurotoxic proteins, including APP and amyloid beta, tau, alpha-synuclein, and TDP-43, through a specific RNA-targeting mechanism of action. By addressing the underlying causes of neurodegeneration, Annovis aims to halt disease progression and improve cognitive and motor functions in patients. The drug is currently in a pivotal Phase 3 clinical trial.
The company's participation in Fierce Biotech Week underscores the growing interest in multi-target therapies for Alzheimer's disease, which has traditionally focused on single protein targets such as amyloid beta. Annovis' approach represents a paradigm shift in neurodegenerative disease research, potentially offering a more comprehensive treatment option.
For more information about Annovis Bio and its pipeline, visit the company's website at www.annovisbio.com. The full press release can be accessed at https://ibn.fm/kZ2Z4. Additional updates are available in the company's newsroom at https://ibn.fm/ANVS.
The presentation at Fierce Biotech Week is significant as it provides a platform for Annovis to share its innovative approach with a broad audience of industry professionals, potentially attracting collaborators and investors. It also highlights the company's commitment to advancing treatments for neurodegenerative diseases that affect millions worldwide.
